National Academies Press: OpenBook
« Previous: 10 Moving Forward: Potential Concrete Legal and Regulatory Actions
Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×

A

References

Ahmad, F. B., L. M. Rossen, and P. Sutton. 2021 Provisional drug overdose death counts. Vital Statistics Rapid Release: National Center for Health Statistics. 2021. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#citation (accessed June 10, 2022).

Almazan, A. N., D. King, C. Grasso, S. Cahill, M. Lattanner, M. L. Hatzenbuehler, and A. S. Keuroghlian. 2021. Sexual orientation and gender identity data collection at US health centers: Impact of city-level structural stigma in 2018. American Journal of Public Health 111(11):2059–2063. https://doi.org/10.2105/AJPH.2021.306414.

APA (American Psychiatric Association). 2022. Diagnostic and statistical manual of mental disorders: DSM-5-TR. Washington, DC: American Psychiatric Association.

Anstice, A., C. J. Strike, and B. Brands. 2009. Supervised methadone consumption: Client issues and stigma, Substance Use & Misuse 44(6):794–808. https://doi.org/10.1080/10826080802483936.

Baumgartner, J. C., and D. C. Radley. 2022. Overdose deaths surged in the first half of 2021, underscoring urgent need for action. The Commonwealth Fund. https://doi.org/10.26099/TMAE-JE82 (accessed April 26, 2022).

Bellamy, C. D., M. Costa, J. Wyatt, M. Mathis, A. Sloan, M. Budge, K. Blackman, L. Ocasio, G. Reis, K. Guy, R. R. Anderson, M. S. Copes, and A. Jordan. 2021. A collaborative culturally-centered and community-driven faith-based opioid recovery initiative: The Imani Breakthrough project. Social Work in Mental Health 19(6):558–567. https://doi.org/10.1080/15332985.2021.1930329.

Binswanger, I. A., M. F. Stern, R. A. Deyo, P. J. Heagerty, A. Cheadle, J. G. Elmore, and T. D. Koepsell. 2007. Release from prison—a high risk of death for former inmates. The New England Journal of Medicine 356(2):157–165. https://doi.org/10.1056/NEJMsa064115.

Bonnie, R. J., C. Davis, B. C. E. Dooling, M. Lawrence, and S. Weizman. 2022. An expedited regulatory strategy for expanding access to methadone treatment for substance use disorders. Health Affairs Forefront. May 27. http://doi.org/10.1377/forefront.20220524.171269.

Bowden, C. L., J. F. Maddux, and M. Esquivel. 1976. Methadone dispensing by community pharmacies. The American Journal of Drug and Alcohol Abuse 3(2):243–254. https://doi.org/10.3109/00952997609077194.

Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×

Bronson, J., J. Stroop, S. Zimmer, and M. Berzofsky. 2017. Drug use, dependence, and abuse among state prisoners and jail inmates, 2007–2009. NCJ 250546. Department of Justice, Bureau of Justice Statistics, Bureau of Justice Statistics. https://bjs.ojp.gov/content/pub/pdf/dudaspji0709.pdf (accessed June 6, 2022).

Brooner, R. K., K. B. Stoller, P. Patel, L. T. Wu, H. Yan, and M. Kidorf. 2022. Opioid treatment program prescribing of methadone with community pharmacy dispensing: Pilot study of feasibility and acceptability. Drug and Alcohol Dependence Reports, p.100067.

Brothers, S., A. Viera, and R. Heimer. 2021. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. Journal of Substance Abuse Treatment 131(December):108449. https://doi.org/10.1016/j.jsat.2021.108449.

Bukten, A., M. R. Stavseth, S. Skurtveit, A. Tverdal, J. Strang, and T. Clausen. 2017. High risk of overdose death following release from prison: Variations in mortality during a 15‐year observation period. Addiction 112(8):1432–1439.

Burns, L., D. Randall, W. D. Hall, M. Law, T. Butler, J. Bell, and L. Degenhardt. 2009. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention. Addiction 104(8):1363–1372. https://doi.org/10.1111/j.1360-0443.2009.02633.x.

CDC (Centers for Disease Control and Prevention). 2021. Quarterly provisional drug overdose estimates with demographics (August). https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm (accessed May 11, 2022).

CDC. 2022. National Center for Health Statistics: Products–Vital statistics rapid release–Provisional drug overdose data. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm (accessed April 26, 2022).

Chang, J. E., B. Franz, C. E. Cronin, Z. Lindenfeld, A. Y. Lai, and J. A. Pagán. 2022. Racial/ethnic disparities in the availability of hospital based opioid use disorder treatment. Journal of Substance Abuse Treatment February. https://doi.org/10.1016/j.jsat.2022.108719.

Coroners Court of Victoria. 2021. Victorian overdose deaths, 2011–2020. https://www.coronerscourt.vic.gov.au/sites/default/files/2021-07/CCOV%20-%20Overdose%20deaths%20in%20Victoria%202011-2020%20-%2029Jul2021.pdf (accessed June 14, 2022).

Drucker, E., S. Rice, G. Ganse, J. J. Kegley, K. Bonuck, and E. Tuchman. 2007. The Lancaster office based opiate treatment program: A case study and prototype for community physicians and pharmacists providing methadone maintenance treatment in the United States. Addictive Disorders & Their Treatment 6:121–135.

Dunn, K. E., R. K. Brooner, K. B. Stoller. 2021. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the COVID-19 pandemic. Journal of Substance Abuse Treatment 121:108197.

Entress, R. M. 2021. The intersection of race and opioid use disorder treatment: A quantitative analysis. Journal of Substance Abuse Treatment 131(December). https://doi.org/10.1016/j.jsat.2021.108589.

Esposito, D., L. Simon, M. Tucker, J. Stangle, T. Moore, I. Hill, B. Courtot, E. Burroughs, and K. Witgert. (2021). Maternal Opioid Misuse (MOM) model: Pre-implementation evaluation report. Centers for Medicare & Medicaid Services. https://innovation.cms.gov/data-and-reports/2022/mom-preimp-report (accessed June 13, 2022).

Fiellin, D. A., P. G. O’Connor, M. Chawarski, J. P. Pakes, M. V. Pantalon, and R. S. Schottenfeld. 2001. Methadone maintenance in primary care: A randomized controlled trial. Journal of the American Medical Association 86(14):1724–1731. https://doi.org/10.1001/jama.286.14.1724.

Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×

Figgatt, M. C., Z. Salazar, E. Day, L. Vincent, and N. Dasgupta. 2021. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. Journal of Substance Abuse Treatment 123(April):108276. https://doi.org/10.1016/j.jsat.2021.108276.

Fonseca J., and A. Chang, F. Chang. 2018. Perceived barriers and facilitators to providing methadone maintenance treatment among rural community pharmacists in Southwestern Ontario. Journal of Rural Health 34(1):23–30. doi:10.1111/jrh.12264.

Frank, D., and S. M. Walters. 2021. ‘I’m going to stop myself before someone stops me’: Complicating narratives of volitional substance use treatment. Frontiers in Sociology 6:619677. https://doi.org/10.3389/fsoc.2021.619677.

Frank, D., P. Mateu-Gelabert, D. C. Perlman, S. M. Walters, L. Curran, and H. Guarino. 2021. “It’s like ‘liquid handcuffs’”: The effects of take-home dosing policies on methadone maintenance treatment (MMT) patients’ lives. Harm Reduction Journal 18(1):88. https://doi.org/10.1186/s12954-021-00535-y.

Friedman, J., L. Beletsky, and A. Jordan. 2022. Surging racial disparities in the US overdose crisis. American Journal of Psychiatry 179(2):166–169. https://doi.org/10.1176/appi.ajp.2021.21040381.

Gauthier, G., J. K. Eibl, and D. C. Marsh. 2018. Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies. Drug and Alcohol Dependence 191(October):1–5. https://doi.org/10.1016/j.drugalcdep.2018.04.029.

Girouard, M. P., H. Goldhammer, and A. S. Keuroghlian. 2019. Understanding and treating opioid use disorders in lesbian, gay, bisexual, transgender, and queer populations. Substance Abuse 40(3):335–339. https://doi.org/10.1080/08897077.2018.1544963.

Goedel, W. C., A. Shapiro, M. Cerdá, J. W. Tsai, S. E. Hadland, and B. D. L. Marshall. 2020. Association of racial/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. Journal of American Medicine Association 3(4):e203711. https://doi.org/10.1001/jamanetworkopen.2020.3711.

Goldhammer, H., A. C. Smart, L. A. Kissock, and A. S. Keuroghlian. 2021. Organizational strategies and inclusive language to build culturally responsive health care environments for lesbian, gay, bisexual, transgender, and queer people. Journal of Health Care for the Poor and Underserved 32(1):18–29. https://doi.org/10.1353/hpu.2021.0004.

Hansen, H., C. Siegel, J. Wanderling, and D. DiRocco. 2016. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug and Alcohol Dependence 164(July):14–21. https://doi.org/10.1016/j.drugalcdep.2016.03.028.

Harris, M. T., A. M. Lambert, A. D. Maschke, S. M. Bagley, A. Y. Walley, and C. M. Gunn. 2021. “No home to take methadone to”: Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. Journal of Substance Abuse Treatment 135:108655.

Hatch-Maillette, M. A., K. M. Peavy, J. I. Tsui, C. J. Banta-Green, S. Woolworth, P. Grekin, 2021. Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives. Journal of Substance Abuse Treatment 124:108223.

Hochheimer, M., and G. J. Unick. 2022. Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States. Addictive Behaviors 124:107113.

Hunter, S. B., A. R. Dopp, A. J. Ober, and L. Uscher-Pines. 2021. Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study. Journal of Substance Abuse Treatment 124(May):108288. https://doi.org/10.1016/j.jsat.2021.108288.

Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×

Jones, C. M., M. Campopiano, G. Baldwin, and E. McCance-Katz. 2015. National and state treatment need and capacity for opioid agonist medication-assisted treatment. American Journal of Public Health 105(8):e55–e63. https://doi.org/10.2105/AJPH.2015.302664.

Joseph, G., K. Torres-Lockhart, M. R. Stein, P. A. Mund, and S. Nahvi. 2021. Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. Journal of Substance Abuse Treatment 122(March):108219. https://doi.org/10.1016/j.jsat.2020.108219.

Joudrey, P. J., E. J. Edelman, and E. A. Wang. 2019a. Drive times to opioid treatment programs in urban and rural counties in 5 US states. Journal of the American Medicine Association 322(13):1310–1312. https://doi.org/10.1001/jama.2019.12562.

Joudrey, P. J., M. R. Khan, E. A. Wang, J. D. Scheidell, E. J. Edelman, D. K. McInnes, and A. D. Fox. 2019b. A conceptual model for understanding post-release opioid-related overdose risk. Addiction Science & Clinical Practice 14(1):17. https://doi.org/10.1186/s13722-019-0145-5.

Joudrey, P. J., N. Chadi, P. Roy, K. L. Morford, P. Bach, S. Kimmel, E. A. Wang, and S. L. Calcaterra. 2020. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug and Alcohol Dependence 211(March):107968. https://doi.org/10.1016/j.drugalcdep.2020.107968.

Kecojevic, A., C. F. Wong, S. M. Schrager, K. Silva, J. J. Bloom, E. Iverson, and S. E. Lankenau. 2012. Initiation into prescription drug misuse: Differences between lesbian, gay, bisexual, transgender (LGBT) and heterosexual high-risk young adults in Los Angeles and New York. Addictive Behaviors 37(11):1289–1293. https://doi.org/10.1016/j.addbeh.2012.06.006.

Kecojevic, A., C. F. Wong, H. L. Corliss, and S. E. Lankenau. 2015. Risk factors for high levels of prescription drug misuse and illicit drug use among substance-using young men who have sex with men (YMSM). Drug and Alcohol Dependence 150(May):156–163. https://doi.org/10.1016/j.drugalcdep.2015.02.031.

Keuroghlian, A. S. 2021. Electronic health records as an equity tool for LGBTQIA+ people. Nature Medicine 27(12):2071–2073. https://doi.org/10.1038/s41591-021-01592-3.

Keuroghlian, A. S., S. L. Reisner, J. M. White, and R. D. Weiss. 2015. Substance use and treatment of substance use disorders in a community sample of transgender adults. Drug and Alcohol Dependence 152:139–146.

Khatri, U. G., and T. N. A. Winkelman. 2022. Strengthening the Medicaid Reentry Act—supporting the health of people who are incarcerated. The New England Journal of Medicine, January. https://doi.org/10.1056/NEJMp2119571.

Kidorf, M., R. K. Brooner, K. E. Dunn, J. M. Peirce. 2021. Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic. Journal of Substance Abuse Treatment 126:108328.

Kimmel, S. D., S. Rosenmoss, B. Bearnot, M. Larochelle, and A. Y. Walley. 2021. Rejection of patients with opioid use disorder referred for post-acute medical care before and after an anti-discrimination settlement in Massachusetts. Journal of Addiction Medicine 15(1):20–26. https://doi.org/10.1097/ADM.0000000000000693.

King, V. L., M. S. Kidorf, K. B. Stoller, R. Schwartz, K. Kolodner, and R. K. Brooner. 2006. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. Journal of Substance Abuse Treatment 31(4):385–393. https://doi.org/10.1016/j.jsat.2006.05.014.

Kleinman, R. A. 2020. Comparison of driving times to opioid treatment programs and pharmacies in the US. Journal of American Medicine Association Psychiatry 77(11):1163–1171. https://doi.org/10.1001/jamapsychiatry.2020.1624.

Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×

Krawczyk, N., H. Maniates, E. Hulsey, J. S. Smith, E. DiDomenico, E. A. Stuart, B. Saloner, and S. Bandara. 2022. Shifting medication treatment practices in the COVID-19 pandemic: A statewide survey of Pennsylvania opioid treatment programs. Journal of Addiction Medicine, February. https://doi.org/10.1097/ADM.0000000000000981.

Laks, J., J. Kehoe, N. M. Farrell, M. Komaromy, J. Kolodziej, A. Y. Walley, and J. L. Taylor. 2021. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: A case report applying the 72-hour rule. Addiction Science & Clinical Practice 16(1):73. https://doi.org/10.1186/s13722-021-00279-x.

Larochelle M. R., R. Bernstein, D. Bernson, T. Land, T. J. Stopka, A. J. Rose, M. Bharel, J. M. Liebschutz, and A. Y. Walley. 2019. Touchpoints—Opportunities to predict and prevent opioid overdose: A cohort study. Drug and Alcohol Dependence 1(204):107537. https://doi.org/10.1016/j.drugalcdep.2019.06.039.

Levander, X. A., J.D. Pytell, K. B. Stoller, P.T. Korthuis, G. Chander. 2021a. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership. Substance Abuse 43(1):633–639.

Levander, X. A., K. A. Hoffman, J. W. McIlveen, D. McCarty, J. P. Terashima, and P. T. Korthuis. 2021b. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: A qualitative thematic analysis. Addiction Science & Clinical Practice 16(1):1–10.

Lintzeris, N., M. Lenne, and A. Ritter. 1999. Methadone injecting in Australia: A tale of two cities. Addiction 94(8):1175-1178.

Madden, E. F., B. T. Christian, P. A. Lagisetty, B. R. Ray, S. H. Sulzer. 2021. Treatment provider perceptions of take-home methadone regulation before and during COVID-19. Drug and Alcohol Dependence 228:109100.

Matheson, C. 1998. Privacy and stigma in the pharmacy: Illicit drug users’ perspectives and implications for pharmacy practice. Pharmaceutical Journal 260(6992):639–641.

Matheson, C., C. M. Bond, and J. Pitcairn. 2002. Community pharmacy services for drug misusers in Scotland: What difference does 5 years make? Addiction 97(11):1405–1411. doi: 10.1046/j.1360-0443.2002.00241.x. PMID: 12410781.

McCarty, D., C. Bougatsos, B. Chan, K. A. Hoffman, K. C. Priest, S. Grusing, and R. Chou. 2021. Office-based methadone treatment for opioid use disorder and pharmacy dispensing: A scoping review. The American Journal of Psychiatry 178(9):804–817. https://doi.org/10.1176/appi.ajp.2021.20101548.

Minton, T. D., L. G. Beatty, and Z. Zeng. 2021. Correctional populations in the United States, 2019—Statistical Tables. U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics: NCJ:300655. https://bjs.ojp.gov/sites/g/files/xyckuh236/files/media/document/cpus19st.pdf (accessed May 9, 2022).

NASEM (National Academies of Sciences, Engineering, and Medicine). 2019. Medications for opioid use disorder save lives. Washington, DC: The National Academies Press.

Neale, J. 1999. Drug users’ views of substitute prescribing conditions. International Journal of Drug Policy 10(3):247-258. https://doi.org/10.1097/01.adt.0000210713.80198.d1.

Neale, J., C. N. E. Tompkins, R. McDonald, and J. Strang. 2018. Patient views of opioid pharmacotherapy biodelivery systems: Qualitative study to assist treatment decision making. Experimental and Clinical Psychopharmacology 26(6):570–581. https://doi.org/10.1037/pha0000217.

NIDA (National Institute on Drug Abuse). 2021. Medications to treat opioid disorder research report: How much does opioid treatment cost? https://nida.nih.gov/publications/research-reports/medications-to-treat-opioid-addiction/how-much-does-opioid-treatment-cost (accessed June 12, 2022).

Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×

Nielsen, S., A. Cheetham, J, Jackson, S. Lord, D. Petrie, D. Jacka, L. Picco, and K. Morgan. 2021. A prospective, multisite implementation-efficacy trial of a collaborative prescriber-pharmacist model of care for medication assisted treatment for opioid dependence: Protocol for the EPIC-MATOD study. Research in Social and Administration Pharmarcy S1551-7411(21)00379-X. https://doi.org/10.1016/j.sapharm.2021.11.007. Epub ahead of print. PMID: 34924314

Peavy, K. M., J. Darnton, P. Grekin, M. Russo, C. J. B. Green, J. O. Merrill, C. Fontinos, S. Woolworth, S. Soth, J. I. Tsui. 2020. Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program. AIDS and Behavior 24(9):2469–2472.

Qato, D. M., S. Zenk, J. Wilder, R. Harrington, D. Gaskin, G. C. Alexander. 2017. The availability of pharmacies in the United States: 2007–2015. PloS One 12:e0183172.

Ranapurwala, S. I., M. E. Shanahan, A. A. Alexandridis, S. K. Proescholdbell, R. B. Naumann, D. Edwards, S. W. Marshall. 2018. Opioid overdose mortality among former North Carolina inmates: 2000–2015. American Journal of Public Health 108(9):1207–1213.

Rieckmann, T., L. Moore, C. Croy, G. A. Aarons, and D. K. Novins. 2017. National overview of medication-assisted treatment for American Indians and Alaska Natives with substance use disorders. Psychiatric Services (Washington, DC) 68(11):1136–1143. https://doi.org/10.1176/appi.ps.201600397.

SAMHSA (Substance Abuse and Mental Health Services Administration). 2015. Federal guidelines for opioid treatment programs. https://store.samhsa.gov/product/Federal-Guide-lines-for-Opioid-Treatment-Programs/PEP15-FEDGUIDEOTP (accessed April 26, 2022).

SAMHSA. 2019. Key substance use and mental health indications in the United States: Results from the 2018 National Survey on Drug Use and Health. (HHS Publication No. PEP195068, NSDUH Series H-54). https://www.samhsa.gov/data (accessed April 26, 2022).

SAMHSA. 2020. Medications for opioid use disorder: Treatment protocol (Tip) Series 63. https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-02-01-006.pdf (accessed May 6, 2022).

SAMHSA. 2021. Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP2107-01-003, NSDUH Series H-56). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/ (accesed June 8, 2022).

Schiff, D. M., T. Nielsen, B. B. Hoeppner, M. Terplan, H. Hansen, D. Bernson, H. Diop, M. Bharel, E. E. Krans, S. Selk, J. F. Kelly, T. E. Wilens, and E. M. Taveras. 2020. Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts. Journal of American Medicine Association 3(5)e205734. https://doi.org/10.1001/jamanetworkopen.2020.5734.

Scott, C.K., M. L. Dennis, C. E. Grella, A. F. Mischel, and J. Carnevale. 2021. The impact of the opioid crisis on U.S. state prison systems. Health Justice 9:17. https://doi.org/10.1186/s40352-021-00143-9

Senay, E. C., A. G. Barthwell, R. Marks, P. Bokos, D. Gillman, R. White, and C. A. Pristach. 1993. Medical maintenance: A pilot study. Journal of Addictive Diseases 12(4):59–76.

Strang, J., W. Hall, M. Hickman, and S. M. Bird. 2010. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): Analyses using OD4 index in England and Scotland. British Medical Journal 341:c4851 doi:10.1136/bmj.c485 - https://www.bmj.com/content/341/bmj.c4851

Suen, L. W., S. Castellanos, N. Joshi, S. Satterwhite, and K. R. Knight. 2021. “The idea is to help people achieve greater success and liberty”: A qualitative study of expanded methadone take-home access in opioid use disorder treatment. medRxiv. https://doi.org/10.1101/2021.08.20.21262382.

Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×

Taylor, J. L., J. Laks, P. J. Christine, J. Kehoe, J. Evans, T. W. Kim, N. M. Farrell, C. S. White, Z. M. Weinstein, and A. Y. Walley. 2022. Bridge clinic implementation of “72-hour rule” methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care. Drug and Alcohol Dependence 236:109497.

Tran A. D., R. Chen, S. Nielsen, E. Zahra, L. Degenhardt, T. Santo, M. Farrell, and B. Larance. 2022. Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions. International Journal of Drug Policy 99:103472. doi: 10.1016/j.drugpo.2021.103472.

Trowbridge, P., Z. M. Weinstein, T. Kerensky, P. Roy, D. Regan, J. H. Samet, and A. Y. Walley. 2017. Addiction consultation services—Linking hospitalized patients to outpatient addiction treatment. Journal of Substance Abuse Treatment 79(August):1–5. https://doi.org/10.1016/j.jsat.2017.05.007.

U.S. Census Bureau. 2012. 2010 Census show nearly half of American Indians and Alaska Natives report multiple races. Newsroom Archive. https://www.census.gov/newsroom/releases/archives/2010_census/cb12-cn06.html (accesed June 12, 2022).

Wagner, P., and B. Rabuy. 2017. Following the money of mass incarceration. Prison Policy Initiative, January 25. https://www.prisonpolicy.org/reports/money.html (accessed June 12, 2022).

Walley, A. Y., S. Lodi, Y. Li, D. Bernson, H. Babakhanlou-Chase, T. Land, and M. R. Larochelle. 2020. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: A cohort analysis. Addiction (Abingdon, England) 115(8):1496–1508. https://doi.org/10.1111/add.14964.

White, W. L., C. K. Scott, M. L. Dennis, and M. G. Boyle. 2005. It’s time to stop kicking people out of addiction treatment. Counselor (Deerfield Beach, FL) 6(2):12.

Winkelman, T. N. A., V. W. Chang, and I. A. Binswanger. 2018. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. Journal of American Medicine Association 1(3):e180558. https://doi.org/10.1001/jamanetworkopen.2018.0558.

Wu, L., H. Zhu, and M. S. Swartz. 2016. Treatment utilization among persons with opioid use disorder in the United States. Drug and Alcohol Dependence 169(December):117–127. https://doi.org/10.1016/j.drugalcdep.2016.10.015.

Wu, L., W. S. John, U. E. Ghitza, A. Wahle, A. G. Matthews, M. Lewis, B. Hart, Z. Hubbard, L. A. Bowlby, L. H. Greenblatt, and P. Mannelli. 2021. Buprenorphine physician–pharmacist collaboration in the management of patients with opioid use disorder: Results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network. Addiction (Abingdon, England) 116(7):1805–1816. https://doi.org/10.1111/add.15353.

Wu, L., W. S. John, E. D. Morse, S. Adkins, J. Pippin, R. K. Brooner, and R. P. Schwartz. 2022. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: Results from a feasibility clinical trial. Addiction 117(2):444–456. https://doi.org/10.1111/add.15641.

Zeng, Z. 2020. Jail inmates in 2018. U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. https://bjs.ojp.gov/library/publications/jail-inmates-2018 (accessed May 9, 2022).

Zule, W. A., C. Oramasionwu, D. Evon, S. Hino, I. A. Doherty, G. V. Bobashev, and W. M. Wechsberg. 2016. Event-level analyses of sex-risk and injection-risk behaviors among nonmedical prescription opioid users. The American Journal of Drug and Alcohol Abuse 42(6):689–697. https://doi.org/10.1080/00952990.2016.1174706.

Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×

This page intentionally left blank.

Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×
Page 117
Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×
Page 118
Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×
Page 119
Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×
Page 120
Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×
Page 121
Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×
Page 122
Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×
Page 123
Suggested Citation:"Appendix A: References." National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26635.
×
Page 124
Next: Appendix B: Workshop Agenda »
Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop Get This Book
×
Buy Paperback | $25.00 Buy Ebook | $20.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Methadone is a Food and Drug Administration- (FDA-) approved medication for treating opioid use disorder (OUD), a chronic brain disease that affects more than 2.7 million people in the United States aged 12 and older. Despite its effectiveness in saving lives, many barriers impede access to, initiation of, and retention in methadone treatment for OUD. To address these barriers, on March 3 and 4, 2022, the National Academies of Sciences, Engineering, and Medicine hosted a workshop on "Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Laws," at the request of the Office of National Drug Control Policy in the Executive Office of the President. This publication summarizes the presentation and discussion of the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!